FY2026 EPS Estimates for AbbVie Increased by Leerink Partnrs

AbbVie Inc. (NYSE:ABBV) – Research analysts at Leerink Partnrs lifted their FY2026 earnings estimates for shares of AbbVie in a research note issued to investors on Friday, November 22nd. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of $13.69 for the year, up from their prior forecast of $13.67. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $10.95 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2027 earnings at $15.36 EPS and FY2028 earnings at $16.79 EPS.

ABBV has been the topic of a number of other research reports. William Blair raised AbbVie to a “strong-buy” rating in a research report on Friday, August 30th. BMO Capital Markets lowered their price objective on AbbVie from $228.00 to $208.00 and set an “outperform” rating for the company in a research report on Tuesday, November 12th. Piper Sandler raised their price target on AbbVie from $196.00 to $209.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. TD Cowen increased their price objective on shares of AbbVie from $195.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Finally, Truist Financial boosted their price objective on shares of AbbVie from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $203.50.

AbbVie Trading Up 0.1 %

NYSE:ABBV opened at $177.06 on Monday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The firm has a 50-day simple moving average of $189.09 and a 200-day simple moving average of $181.44. AbbVie has a one year low of $137.65 and a one year high of $207.32. The firm has a market cap of $312.89 billion, a P/E ratio of 61.48, a P/E/G ratio of 2.16 and a beta of 0.63.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.92 by $0.08. The company had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. AbbVie’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the business posted $2.95 EPS.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $1.64 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.55. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.70%. AbbVie’s payout ratio is presently 227.78%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ABBV. Fairway Wealth LLC purchased a new stake in AbbVie during the 2nd quarter valued at about $26,000. Ridgewood Investments LLC purchased a new stake in shares of AbbVie in the second quarter valued at approximately $27,000. Groupama Asset Managment increased its holdings in shares of AbbVie by 40.3% in the third quarter. Groupama Asset Managment now owns 135,749 shares of the company’s stock valued at $27,000 after purchasing an additional 38,974 shares during the last quarter. RPg Family Wealth Advisory LLC purchased a new position in AbbVie during the third quarter worth approximately $28,000. Finally, Quest Partners LLC boosted its stake in AbbVie by 4,140.0% during the second quarter. Quest Partners LLC now owns 212 shares of the company’s stock worth $36,000 after buying an additional 207 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.